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Abstract
Background—Therapeutic effects of antiretroviral therapy (ART) in patients with multidrug 
resistant tuberculosis (MDR-TB) and HIV infection have not been established.
Objective—The objective of this study was to assess therapeutic outcomes of ART integration 
with MDR-TB treatment.
Design—A subgroup of MDR-TB patients from the SAPiT study, a randomized controlled trial, 
conducted in an out-patient clinic in Durban, South Africa from 2008–2012
Methods—Clinical outcomes at 18 months were compared in patients randomized to receive 
ART within 12 weeks of standard first-line tuberculosis treatment initiation with those who 
commenced ART after completing tuberculosis treatment.
Results—Mycobacterium tuberculosis drug susceptibility was available in 489 (76%) of 642 
SAPiT patients; 23 had MDR-TB, 14 in the integrated treatment arm and 9 in the sequential 
treatment arm. At 18 months, the mortality rate was 11.9/100 person-years (95% confidence 
interval (CI): 1.4–42.8) in the combined integrated treatment arm and 56.0/100 person-years 
(95%CI: 18.2–130.8) in the sequential treatment arm, (Hazard Ratio adjusted for baseline CD4 
count and whether MDR-TB treatment was initiated: 0.14; 95% CI: 0.02–0.94; P=0.04).
Conclusion—Despite the small sample size, the 86% reduction in mortality due to early 
initiation of ART in MDR-TB patients was statistically significant.
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Multi-drug resistant tuberculosis (MDR-TB), defined as resistance to at least isoniazid and 
rifampicin is a major cause of mortality in tuberculosis-HIV co-infected patients. The 
number of reported MDR-TB cases in South Africa rose from 6795 in 2008(1) to 10 085 in 
2011,(2) among the highest in the world. Of the 6795 reported MDR-TB cases in 2008, 28% 
(N=1866) occurred in the province of KwaZulu-Natal.(3) 76% were co-infected with 
HIV. (4, 5)
The SAPiT trial(6) showed that the initiation of antiretroviral therapy (ART) during 
tuberculosis treatment in patients with mostly drug susceptible tuberculosis and HIV co-
infection reduced mortality by 56%. Based on these and other findings,(7, 8) the 2010 South 
African National ART guidelines were changed; stating that patients co-infected with MDR-
TB and HIV should be commenced on ART irrespective of CD4+ cell count.(9)
Empiric evidence for survival benefit of early initiation of ART in patients with MDR-TB is 
lacking. The SAPiT trial offers an opportunity to provide such information.(6) The purpose 
of this subgroup analysis of the SAPiT trial was to assess the impact, through a randomized 




This is a secondary analysis of 23 patients diagnosed with MDR-TB from the SAPiT trial, 
an open-label, randomized controlled trial between June 2005 and July 2010, which has 
been described in detail elsewhere.(6)
Setting and Participants
The study was conducted at the CAPRISA eThekwini clinic in Durban, South Africa. 
Ambulatory patients, 18 years or older with pulmonary tuberculosis and HIV co-infection 
were enrolled. For this analysis, only patients with Mycobacterium tuberculosis (M 
tuberculosis) resistant to at least rifampicin and isoniazid were classified as MDR-TB cases. 
Other resistance patterns were classified as ‘non-MDR’.
Randomization and interventions
Participants were randomized to start ART either during the first 12 weeks of tuberculosis 
treatment (combined integrated treatment arm) or upon tuberculosis treatment completion 
(sequential treatment arm). The once daily ART regimen contained didanosine, lamivudine 
and efavirenz. ART adherence was assessed by pill counts. CD4+ cell counts and HIV RNA 
levels were performed at screening, randomization and at 6-monthly intervals. All patients 
received anti-tuberculosis therapy comprising rifampicin, isoniazid, ethambutol and 
pyrazinamide during the intensive phase and rifampicin and isoniazid during the 
continuation phase unless they were diagnosed with MDR-TB. Patients treated for MDR-TB 
received the standard MDR-TB regimen of kanamycin, ofloxacin, pyrazinamide, 
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ethambutol/ cycloserine and ethionamide. M tuberculosis was cultured on MGIT and 7H11 
Middlebrook medium with drug susceptibility testing by the 1% proportion method.
Outcomes and follow-up
Prior to 2007, in accordance with the existing South African National Tuberculosis Control 
Programme guidelines,(10) drug susceptibility testing for M. tuberculosis was only 
performed when drug resistance was suspected. From 2007 onwards, drug susceptibility 
testing became routinely available and was performed at enrolment and retrospectively for 
those already enrolled but not previously tested. The median time from specimen collection 
to receipt of drug susceptibility result was 3 months (range 2–9 months). The follow-up 
period was 18 months.
Statistical Analysis
All analyses were by intention-to-treat in the subgroup of patients who had drug 
susceptibility results. Fisher’s exact test was used for categorical data and unpaired t-tests or 
the Wilcoxon two-sample test for continuous data. The time on study was calculated as the 
time from randomization to death, or termination from the trial, or 18 months on the study, 
whichever occurred first. All patients were censored at 18 months if still in follow-up at that 
point. Poisson approximations were used to calculate confidence intervals (CIs) for 
incidence rates. The CIs for the incidence rate ratios (IRRs) were calculated using the F-
distribution. The proportional hazards assumption was checked by fitting a model with the 
interaction between each covariate and time. Only one interaction was statistically 
significant. In the instance where this assumption was violated we reported the IRR instead 
of the hazard ratio. Missing data was not imputed, and because of the small sample size, 
pattern mixture models were not employed for missing data. The total number of data points 
analysed is given and available data is presented and analysed. The missing data mechanism 
is likely to be missing at random. The statistical analysis was performed using SAS version 
9.2
Ethics
The trial was approved by the University of KwaZulu-Natal Biomedical Research Ethics 
Committee (E:07/05).
RESULTS
The SAPiT trial enrolled 642 HIV-tuberculosis co-infected patients and 489 (76%) had 
sputum culture and drug susceptibility testing for M tuberculosis performed. Prior to 2007, 
56 patients had susceptibility testing performed when drug resistance was suspected. After 
2007, when drug susceptibility testing was routinely available, 389 were tested for resistance 
at enrolment and 44 were tested at a follow-up visit as part of the routine testing. 23 of 489 
(5%) patients were diagnosed with MDR-TB (Figure 1), of which 11 of 23 had no past 
history of tuberculosis. At baseline, patients with MDR-TB had lower Karnofsky scores(11), 
were more often WHO stage 4 and presented more frequently with extra-pulmonary 
tuberculosis (Table 1).
Padayatchi et al. Page 3













At baseline, MDR-TB patients in the combined integrated treatment arm (14/322 = 4.3%) 
and the sequential treatment arm (9/167 = 5.4%; Table 1) were similar. Of the 14 patients in 
the combined integrated treatment arm, nine were diagnosed with MDR-TB on their 
enrolment sputum specimen, one during the study (but had no enrolment susceptibility 
testing) and four had susceptible M tuberculosis at enrolment and subsequently developed 
MDR-TB. Of the nine patients in the sequential treatment arm, two were diagnosed with 
MDR-TB on their enrolment sputum specimen, 3 during the course of treatment (but had no 
enrolment susceptibility testing) and four had susceptible M tuberculosis at enrolment and 
subsequently developed MDR-TB. One of the 14 patients in the combined integrated 
treatment arm and none in the sequential treatment arm had extensively drug resistant 
tuberculosis.
Seven of the 23 (30%) MDR-TB patients died; two in the combined integrated treatment 
arm and five in the sequential treatment arm. Death rates were similar in the two treatment 
arms until 6 months (Figure 2). After 6 months, more patients died in the sequential 
treatment arm compared to the integrated treatment arm (Figure 2). The mortality rate in 
MDR-TB patients was 11.9 per 100 person-years (95%CI: 1.4–42.8) in the combined 
integrated treatment arm compared to 56.0 per 100 person-years (95%CI: 18.2–130.8) in the 
sequential treatment arm (HR: 0.14; 95% CI: 0.02–0.94; P=0.04, adjusting for baseline 
CD4+ cell count and whether MDR-TB treatment was initiated). The mortality rate in 
MDR-TB patients was approximately 4-fold higher (P<0.001) than mortality in patients who 
did not have MDR-TB (Table 2a). Irrespective of whether patients received specific 
treatment for MDR-TB, mortality rates were lower in the combined integrated treatment arm 
(Table 2b).
Of the 23 patients with MDR-TB, 14 (61%) started MDR-TB treatment, 64% (9/14) in the 
combined integrated treatment arm, and 56% (5/9) in the sequential treatment arm (Figure 
3). The overall mortality rate in patients who initiated MDR-TB treatment was 10.8 per 100 
person-years (95%CI: 1.3–39.0) and overall mortality rate in patients who did not initiate 
MDR-TB treatment was 68 per 100 person-years (95%CI: 22.3–160.4, P=0.03). After 
adjustment for baseline CD4+ cell count, patients with MDR-TB who had received MDR-
TB treatment had a 93% lower mortality rate at 18 months post-randomization, compared to 
patients who had not initiated MDR-TB treatment (P=0.02). Initiating MDR-TB treatment 
(in those patients who survived long enough to receive their MDR-TB diagnosis) or being in 
the combined integrated treatment arm reduced the risk of dying by 97%, adjusting for 
baseline CD4+ cell count (P=0.003).
Seven patients initiated MDR-TB treatment within 6 months of starting standard 
tuberculosis treatment and only 1/7 (14%) died (Figure 3). In contrast, 16 patients either did 
not start MDR-TB treatment or started MDR-TB treatment more than 6 months after 
standard tuberculosis treatment, and 6/16 (38%) died (RR 0.38; 95% CI: 0.06–2.60; 
P=0.37). In this latter group, 1/8 (13%) patients in the combined integrated treatment arm 
died and 5/8 (63%) patients in the sequential treatment arm died (RR: 0.20; 95%CI: 0.03–
1.35; P=0.12).
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In the combined integrated treatment arm, the median time from ART to MDR-TB treatment 
was 113 (range: 40–239) days(n=6) and in the Sequential treatment arm it was 258 days - 
only one patient started ART before MDR-TB treatment (Figure 3)
The reasons for not commencing MDR-TB treatment in the combined integrated arm were: 
lost to follow up (n=2), death(n=1) and response to 1st line TB drugs before commencing 
treatment for MDR-TB(n=2); in the sequential arm, 4 patients died before commencing 
treatment for MDR-TB.
In the combined integrated treatment arm, one patient was diagnosed with MDR-TB 
posthumously; he had not received MDR-TB treatment but had received ART for 2.5 
months before he died from severe diarrhoea. The other death in this arm was due to suicide 
and occurred after 4 months of MDR-TB treatment and 5 months of ART. In the sequential 
treatment arm, four patients were diagnosed with MDR-TB posthumously; none had 
received MDR-TB treatment while one had received ART for 3 months before he died; the 
fifth patient had not initiated ART and had been treated for MDR-TB for 19 days prior to 
death. Clinical outcomes of tuberculosis treatment (some on standard tuberculosis treatment 
and others on MDR-TB treatment) were available in 19 of the 23 MDR-TB patients; four 
were lost to follow-up in the combined integrated treatment arm. At 18 months, seven 
patients had died, six were still receiving MDR-TB treatment (four in the combined 
integrated arm and two in the sequential treatment arm) and a further six were cured [four in 
the combined integrated treatment arm and two in the sequential treatment arm (P=1.00)].
At 12 months of follow-up, 78% (N=9) in the combined integrated treatment arm and all 
four in the sequential treatment arm had undetectable viral loads. The mean increase in 
CD4+ cell count was 108 and 89.8 cells/mm3 in the combined integrated and sequential 
treatment arms respectively (Table 3).
DISCUSSION
Initiation of ART during tuberculosis treatment in patients with MDR-TB was associated 
with an 86% reduction in mortality. This survival benefit associated with ART initiation was 
evident even in patients who had not initiated appropriate MDR-TB treatment. Similar 
survival benefits have also been observed in retrospective studies among XDR-TB patients 
who were co-infected with HIV and received ART.(12, 13)
The long laboratory delays in the diagnosis of MDR-TB delays initiation of appropriate 
treatment and contributes to high mortality among MDR-TB patients. Patients with MDR-
TB in this study experienced a 4-fold higher rate of mortality compared to those with non 
MDR-TB. Similar high mortality rates have been observed in patients co-infected with 
MDR-TB and HIV in rural KwaZulu-Natal, where 40% of MDR-TB cases died within 30 
days of sputum collection, most dying before the diagnosis of MDR-TB was confirmed.(5) A 
retrospective review conducted in Thailand showed that HIV and MDR-TB co-infected 
patients were 12-times more likely to die than patients without MDR-TB.(14)
A consequence of the diagnostic and treatment initiation delays resulted in MDR-TB 
confirmation posthumously in this study. This is not unique. In a post mortem study of 240 
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individuals (94% HIV-infected), 17% had MDR TB that had not been recognized 
clinically.(15) Therefore, initiating ART during tuberculosis treatment provides an 
opportunity to improve survival rates until MDR-TB can be confirmed and appropriate 
treatment instituted. It is quicker to diagnose HIV, institute ART and improve survival until 
MDR-TB can be diagnosed and MDR-TB treatment initiated. If MDR-TB can be diagnosed 
early and both ART and MDR-TB treatment initiated mortality is likely to be reduced even 
further.(12, 13, 16)
Although MDR-TB patients in this study were more often categorized as WHO stage 4 and 
had extra-pulmonary tuberculosis, these criteria were insufficient indicators of which 
patients had MDR-TB. Immune markers such as CD4+ cell count and viral load were 
similar among MDR-TB patients and those with drug susceptible tuberculosis. Other studies 
have also shown that the clinical and radiological presentation for patients with MDR-TB 
and drug susceptible tuberculosis is similar.(17)
Another factor contributing to the delay in investigation of possible MDR-TB is that 
immune reconstitution inflammatory syndrome (IRIS) was considered for MDR-TB patients 
in the combined integrated treatment arm. In addition to a higher index of suspicion for drug 
resistance, there is an urgent need for earlier case finding, better diagnostics, as well as 
integration of tuberculosis and HIV care and treatment.(18)
The MDR-TB case load in KwaZulu-Natal has increased 4-fold between 2002 and 2004, 
with resultant larger numbers of primary MDR-TB cases presenting for tuberculosis 
treatment. Extremely high rates of primary MDR-TB have been reported from specific parts 
of KwaZulu-Natal.(19, 20) A high proportion of MDR-TB patients in these areas with high 
rates of HIV co-infection had no prior history of tuberculosis treatment, in contrast to a 
recent multi-country study which showed that a history of previous tuberculosis was the 
strongest risk factor for MDR-TB.(21, 22) It is also important to note that eight patients in our 
study initially had confirmed drug susceptible tuberculosis and subsequently developed 
MDR-TB. This sequence suggests either selection of resistant organisms while on 
tuberculosis treatment or super-infection with MDR-TB,(23) emphasizing the critical 
importance of strengthening both treatment adherence and infection control in tuberculosis 
programs.
In the SAPiT study participants in each arm were monitored and evaluated using the same 
standardized criteria and practices to minimize bias during the study implementation thus 
preserving external validity. One of the main limitations of this study is the small sample 
size. Despite this, the results were statistically significant due to the large effect size 
observed. This was a post hoc analysis and the study was not designed to screen patients for 
MDR-TB and randomize these patients to early or sequential ART initiation. Newer 
technology now makes the earlier diagnosis of drug resistance possible.(24, 25) Even though 
randomization was not stratified on MDR-TB status, the participants who had undetected 
MDR-TB at baseline constituted a similar proportion of patients in each treatment arm. Thus 
studying this subgroup of patients preserves the benefits of randomization. When the SAPiT 
trial was initiated, it was not possible to conduct such a study because of the delays in 
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obtaining drug susceptibility results and many of the patients died (5 of the 7 deaths) even 
before they were diagnosed with MDR-TB.
The use of all-cause mortality is also a limitation. For example, the death by suicide is 
treated as an equivalent primary endpoint to tuberculosis meningitis. The SAPiT trial 
included 18 months of follow up but some patients with MDR-TB were diagnosed late 
during the study and their clinical outcomes were not known as they were still on the 
required long course of MDR-TB treatment.
Despite these limitations, our study provides empirical evidence from a randomized 
controlled trial of a survival benefit when ART is initiated early in patients with MDR-TB. 
Even though there may be concerns about patient acceptability of integrated therapy, 
retrospective studies have shown a decreased mortality with integrated TB-HIV treatment in 
MDR and XDR-TB despite protracted and complex TB treatment regimens.(5, 12)
In this study, although MDR-TB mortality was high compared to non-MDR-TB cases, 
survival was significantly improved when ART was initiated, even among those who had 
not yet been initiated on MDR-TB treatment. Early ART initiation is desirable in settings 
with high MDR-TB prevalence, especially in sick patients and those with low CD4+ cell 
counts(26) because treatment initiation even before MDR-TB is diagnosed has a survival 
benefit.
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Enrolment and outcomes of patients with MDR-TB and non MDR-TB in the SAPiT trial
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Kaplan Meier curve of the survival probability of patients diagnosed with MDR-TB
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Time to initiation of MDR-TB treatment and ART in relation to standard TB treatment per 
patient
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Table 2b
Mortality rates of patients with MDR-TB in the Combined Integrated and Sequential SAPiT trial arms 
stratified by MDR-TB treatment
Started MDR-TB treatment
during the study period
N=14
Did not start MDR-TB














N 9 5 5 4
Person-years of follow up 11.8 6.7 5.1 2.2
Mortality events 1 1 1 4










Hazard ratio (95% CI) 0.59(0.04 – 9.43) P = 0.71
0.15
(0.02 – 1.41) P = 0.10
MDR-TB: Multidrug resistant tuberculosis
CI: Confidence interval
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